Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Formula recall strategy

This article was originally published in The Tan Sheet

Executive Summary

FDA received no comments on its infant formula recall strategy, the agency says in a June 24 Federal Register notice. The proposed information collection was submitted to the Office of Management and Budget for review and clearance, though comments on the collection may be submitted to OMB through July 24. In a March 26 Federal Register notice, FDA invited comment on enhancing the quality, utility and clarity of collected information (1"The Tan Sheet" March 31, 2008, In Brief)...

You may also be interested in...



Infant formula recalls

FDA is allowing 60 days for public comment regarding the requirements of its recall infant formula strategy, the agency announces in a March 26 Federal Register notice. Specifically, FDA invites comment on "ways to enhance the quality, utility and clarity of the information to be collected" and "ways to minimize the burden of the collection of information on respondents." Currently, firms initiating a recall are required to submit written report to FDA within 14 days and status reports every 14 days until the recall is terminated, among other requirements. The agency says there has been an average of two infant formula recalls per year for the past three years...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS101821

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel